New Oncology Drugs, New Indications, and New Dosing Approved by the FDA.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 6, p. 346
- Publication type:
- Article
Works matching IS 21641153 AND DT 2022 AND VI 12 AND IP 6
Results: 7
1
2
The Presence of De Novo EGFR T790M Mutation in a Tyrosine Kinase Inhibitor-Naïve Patient with Lung Adenocarcinoma: Case Report and Review of the Literature.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 6, p. 340
- By:
- Publication type:
- Article
3
Neoadjuvant FOLFIRINOX Therapy for a Patient with Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Hemodialysis: Case Report.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 6, p. 334
- By:
- Publication type:
- Article
4
Pancreatic Cancer: Review of the Current and Investigational Drug Landscape.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 6, p. 323
- By:
- Publication type:
- Article
5
Outcomes and Adverse Events Linked to Off-Label Treatment of Solid Tumors with PARP Inhibitors.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 6, p. 318
- By:
- Publication type:
- Article
6
Assessment of the Elimination of Test Doses for Paclitaxel and Carboplatin in Patients with Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 6, p. 313
- By:
- Publication type:
- Article
7
Incidence of Hypothyroidism in Patients with Cancer Receiving Immune Checkpoint Inhibitors.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2022, v. 12, n. 6, p. 299
- By:
- Publication type:
- Article